Despite the mildness of the dominant omicron variant and the evidence that the Pfizer COVID-19 vaccine hasn’t stopped infection or transmission of SARS-CoV-2 while posing serious health risks, the company’s CEO is asking the FDA to grant emergency use authorization for a second booster, a fourth shot.
